Alterity Therapeutics Limited
Alterity Therapeutics Limited (ATHE) Revenue
Annual & quarterly revenue history · segment & region breakdown
ATHE · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAlterity Therapeutics Limited trailing twelve-month (TTM) revenue is $0.01B, an increase of 35.32% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-06-30 | $0.01B | +$0.00B | +35.32% |
| 2024-06-30 | $0.00B | +$0.00B | +2.63% |
| 2023-06-30 | $0.00B | -$0.00B | -23.56% |
| 2022-06-30 | $0.01B | +$0.00B | +18.06% |
| 2021-06-30 | $0.00B | +$0.00B | — |
| 2020-06-30 | $0.00B | -$0.00B | -100.00% |
| 2019-06-30 | $0.00B | -$0.00B | -46.05% |
| 2018-06-30 | $0.00B | +$0.00B | +51.95% |
| 2017-06-30 | $0.00B | -$0.00B | -7.19% |
| 2016-06-30 | $0.00B | -$0.00B | -19.33% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Alterity Therapeutics Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Alterity Therapeutics Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in AUD.
Data sourced from Alterity Therapeutics Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
ATHE revenue · 4 questionsATHE's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 35.32% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Alterity Therapeutics Limited SEC filings · GAAP · Alterity Therapeutics Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026